

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau**B3**

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (51) International Patent Classification ⁶ : A61K 31/54 | A1 | (11) International Publication Number: WO 98/52572 (43) International Publication Date: 26 November 1998 (26.11.98) |
| (21) International Application Number: PCT/US98/10494 (22) International Filing Date: 22 May 1998 (22.05.98) (30) Priority Data: 60/047,642 22 May 1997 (22.05.97) US (71) Applicant (for all designated States except US): OKLAHOMA MEDICAL RESEARCH FOUNDATION [US/US]; 825 N.E. 13th Street, Oklahoma City, OK 73104 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): MORRISSEY, James, H. [US/US]; 228 W. Eubanks, Oklahoma City, OK 73118 (US). HAMIK, Anne [US/US]; 1020 N.W. 34th Street, Oklahoma City, OK 73118 (US). (74) Agents: HANSEN, Eugenia, S. et al.; Sidley & Austin, Suite 3400, 717 N. Harwood, Dallas, TX 75201-6507 (US). | | (81) Designated States: AU, CA, JP, US, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>With amended claims.</i> |
| (54) Title: USE OF TAUROLIDINE FOR TREATMENT OF LEUKEMIAS (57) Abstract Taurolidine (taurolin; tauroline; 4,4'-methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide) has been found to be an effective agent for treating patients inflicted with monocytic and/or myeloid leukemias through the induction of apoptosis in leukemia cells. Concentrations of taurolidine in the range of 50 to 100 µg/ml induced apoptosis in 75 % of peripheral blood monocytes incubated in culture medium within six hours. Further, 100 µg/ml taurolidine induced apoptosis in 92 % of granulocytes incubated in culture medium within six hours. Taurolidine was also effective in reducing the hypercoagulable state associated with tissue factor expression on leukemia cells, providing a means by which the incidence and degree of severity of coagulopathies associated with tissue factor expression can be reduced in leukemia patients. Preferred therapeutic dosages for treatment of leukemias are from about 10 to about 500 mg/kg body weight. Most preferred is a dose that results in a 200 µg/ml concentration in the plasma, which is typically about 150 mg/kg body weight. | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|----|--------------------------|----|------------------------------------------|----|----------------------------------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |
| EE | Estonia | | | | | | |

USE OF TAUROLIDINE FOR TREATMENT OF LEUKEMIAS

TECHNICAL FIELD

The invention relates to selective induction of cell death by apoptosis and applicability to treatment of leukemias.

5 CROSS REFERENCE TO RELATED APPLICATION

This application claims the benefit of prior filed copending U.S. Provisional Application No. 60/047,642 filed May 22, 1997.

BACKGROUND OF THE INVENTION

Cell death proceeds by one of two mechanisms: necrosis or apoptosis. In necrosis, the cells lyse and cytosolic components are released. The released cytosolic components elicit severe inflammatory responses. Apoptosis does not result in the release of cytosolic contents, as the cell membrane remains intact even though its surface properties may change. Apoptosis may include the break up of cells into apoptotic bodies, spherical pieces of cells in which the membrane still prevents the release of cytosolic contents. Apoptotic cells and apoptotic bodies are removed in the body by phagocytic cells which are believed to recognize the need to remove such cells by the changes in the outer leaflet of the membrane, in which phosphatidylserine is exposed. Apoptosis typically does not provoke inflammatory responses the way necrosis does because in the former case, the cells are removed by phagocytosis before the cytosolic content is released.

Although cells undergoing apoptosis in vitro initially have intact cell membranes, cells in advanced stages of apoptosis can exhibit loss of membrane integrity. This process is sometimes called "secondary necrosis." It can be observed owing to the absence of phagocytic cells, which in vivo would have removed the apoptotic cells and cell fragments before they could become necrotic.

When neoplastic (tumor) cells are present in the body, it is desirable to cause the death of such cells without causing the death of the normal cells which the patient needs to sustain his life. It is desirable to cause the death of neoplastic cells by inducing apoptosis, so that the cytosolic contents of the neoplastic cells are not released.

Antineoplastic drugs have been reported which kill tumor cells by inducing apoptosis. While some of these drugs have been successful in treating some types of cancer, the drugs have also been known to induce severe side effects, such as cytotoxicity to normal cells by interference with basic cellular functions such as protein synthesis or DNA replication. A few inducers of apoptosis in monocytes have been reported. For example, human blood monocytes can undergo apoptosis

when cultured in the absence of serum or stimulatory factors (which is impossible to achieve *in vivo*). Mangan, et al., "Lipopolysaccharide, tumor necrosis factor- α , and IL-1 β prevent programmed cell death (apoptosis) in human peripheral blood monocytes," *J Immunol* 146:1541 (1991). This process takes two to three days for approximately 50% of the monocytes to become apoptotic (Mangan, et al., "IL-4 enhances programmed cell death (apoptosis) in stimulated human monocytes," *J Immunol* 148:1812 (1992)), and apoptosis can be postponed by lipopolysaccharide (LPS), interleukin (IL)-1, and α -tumor necrosis factor (TNF α). In addition, the anti-inflammatory cytokine IL-4 can enhance apoptosis in LPS-stimulated monocytes. Mangan, D.F. and Wahl, S.M., "Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines," *J Immunol* 147:3408-3412 (1991). Apoptosis has also been induced in several different cell types by the use of a number of cytokines. However, the potential use of cytokines for treatment of cancer *in vivo* has suffered from drawbacks, since they have been reported to elicit a variety of deleterious effects, including shock, circulatory collapse and death. In addition, the manufacture of cytokines has been to date, complicated and expensive since recombinant technology for manufacturing proteins is not an inexpensive proposition on a large scale basis.

Further adding to the complicated nature of leukemia treatment is the fact that there are many different types of leukemia. In viewing the scheme of hemopoiesis, pluripotent stem cells divide to form either lymphoid stem cells or myeloid stem cells. Lymphocytes are produced from lymphoid stem cells, while monocytes and granulocytes such as neutrophils, eosinophils and basophils are produced from myeloid stem cells. Myeloid stem cells also give rise to erythrocytes and megakaryocytes. Various leukemias resulting from these differentiated cells include lymphocytic leukemia, monocytic leukemia, and myeloid leukemia. Treatment methodologies and prognosis differ depending on the specific type of leukemia.

Particularly difficult to treat are myeloid and monocytic leukemias. Current treatment methods have achieved palliation and not cure. For example, patients having monocytic leukemia are generally thought to have a low cure rate of less than ten percent. A true remission is impossible to achieve because the Ph-positive clone persists in the bone marrow, and intense chemotherapy treatments designed to eliminate or reduce the clone have only provided modest improvements in the length of survival of these patients. Current chemotherapy is designed to keep the patient asymptomatic for long periods of time by maintaining a total white blood count within an acceptable range.

10 It is, therefore, desirable to find a new agent that could selectively cause apoptosis of monocytic, myeloid, and leukemia cells without causing severe side effects that accompany the administration of traditional chemotherapeutic agents. It has now been found that a known composition, taurolidine, can be used for the induction of apoptosis in monocytic and myeloid cells.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph depicting the expression of tissue factor (TF) by lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMC) and Mono Mac 6 (MM6) cell line. PBMC at 1.5×10^7 cells/ml (open squares), or
5 5.6×10^5 cells/ml (closed squares) were cultured in AIM-V supplemented with 0.01% bovine calf serum (AIM-V+0.01% BCS). After treatment with 10 ng/ml LPS, samples were collected for ELISA at the indicated times. Data (mean + SD from samples assayed in quadruplicate) are from a representative experiment. In this experiment, uninduced MM6 cells expressed 160 pg TF per 1×10^6 cells,
10 while induced PBMC expressed less than 1 pg TF per 1×10^6 cells.

Fig. 2A and Fig. 2B are graphs depicting tauroldine inhibition of LPS-induced TF expression by monocytic cells as determined by assay procedures. Fig. 2A represents MM6 cells; Fig. 2B represents PBMC. The cells were induced with LPS (hatched bars: 100 ng/ml LPS in RPMI supplemented with 10% BCS
15 (RPMI+10% BCS); solid bars: 10 ng/ml in AIM-V+0.01% BCS) in the presence of varying concentrations of tauroldine, or with a dilution of the vehicle equivalent to that given to cells receiving 100 μ g/ml tauroldine. After four hours, cells were collected and lysates were prepared for TF ELISA. Data are expressed as percent of TF antigen measured in cells treated with LPS alone (no tauroldine or vehicle).
20 Experiments were performed with duplicate samples and were repeated at least three times. Values shown are mean \pm SEM of all experiments.

Fig. 3A and Fig. 3B are graphs depicting tauroldine inhibition of LPS-induced alpha tissue necrosis factor (TNF α) expression by monocytic cells as determined by assay procedures. Fig. 3A represents MM6 cells; Fig. 3B represents
25 PBMC. The cells were induced with LPS (hatched bars: 100 ng/ml LPS in RPMI+10% BCS; solid bars: 10 ng/ml in AIM-V+0.01% BCS) in the presence of varying concentrations of tauroldine. After four hours, cell supernatants were collected for TNF α ELISA. Data are expressed as percent of TNF α levels measured in cell cultures treated with LPS alone (no tauroldine or vehicle).

Experiments were performed with duplicate samples and were repeated at least three times. Values shown in Fig. 3A are from a representative experiment.

Values shown in Fig. 3B are mean \pm SEM of three experiments.

Fig. 4A and Fig. 4B are graphs depicting cell viability and growth rates following taurolidine treatment as determined by assay procedures. MM6 cells were treated with taurolidine as described in Fig. 3. After aliquots were collected for the lactate dehydrogenase (LDH) assay, the remainder of the culture was rinsed in Hank's balanced salt solution (HBSS) and resuspended in RPMI+10%BCS without taurolidine. Counts of trypan blue-negative cells represented in Fig. 4A and total cell number represented in Fig. 4B were recorded daily thereafter (with the measurement at Day 1 being made immediately after the four hour taurolidine treatment). Conditions were no treatment (open squares); 50 μ g/ml taurolidine (closed squares); 25 μ g/ml taurolidine (open circles); and vehicle alone (closed circles). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

Fig. 5A and 5B depict cell viability and growth rates for MM6 cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01% BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 5A), and total cell number (Fig. 5B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed squares); and vehicle alone (closed triangles). Doubling times were determined under each condition, and expressed as a percentage of the rate of doubling of untreated cells. These values are located to the right of the growth curves in (Fig. 5B). Cells were

subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

Fig. 6A and 6B depict cell viability and growth rates for K562 cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01 % BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 6A), and total cell number (Fig. 6B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed squares); and vehicle alone (closed triangles). Doubling times were determined under each condition, and expressed as a percentage of the rate of doubling of untreated cells. These values are located to the right of the growth curves in (Fig. 6B). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

Fig. 7A and 7B depict cell viability and growth rates for HL-60 cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01 % BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 7A), and total cell number (Fig. 7B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed squares); and vehicle alone (closed triangles). Doubling times were determined under each condition, and expressed as a percentage of the rate of doubling of untreated cells. These

values are located to the right of the growth curves in (Fig. 7B). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

Fig. 8A and 8B depict cell viability and growth rates for REH cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01 % BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 8A), and total cell number (Fig. 8B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed squares); and vehicle alone (closed triangles). Doubling times were determined under each condition, and expressed as a percentage of the rate of doubling of untreated cells. These values are located to the right of the growth curves in (Fig. 8B). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

Fig. 9A and 9B depict cell viability and growth rates for Jurkat cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01 % BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 9A), and total cell number (Fig. 9B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed squares); and vehicle alone (closed triangles). Doubling times were determined under each condition,

and expressed as a percentage of the rate of doubling of untreated cells. These values are located to the right of the growth curves in (Fig. 9B). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

5 Fig. 10A and 10B depict cell viability and growth rates for ECV304 cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01 % BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in
10 RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 10A), and total cell number (Fig. 10B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed
15 squares); and vehicle alone (closed triangles). Doubling times were determined under each condition, and expressed as a percentage of the rate of doubling of untreated cells. These values are located to the right of the growth curves in (Fig. 10B). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

20 Fig. 11A and 11B depict cell viability and growth rates for GM5387 cell line following taurolidine treatment, in terms of % trypan blue negative cells and % cell number, respectively. Cells were treated with various concentrations of taurolidine for 4 hours in AIM-V + 0.01 % BCS. After aliquots were collected for LDH assay, the remainder of the culture was rinsed in HBSS and resuspended in
25 RPMI + 10% BCS without taurolidine. Counts of trypan blue-negative cells (Fig. 11A), and total cell number (Fig. 11B), were recorded daily thereafter (with the measurement at Day 1 being made immediately after the 4 hour taurolidine treatment). Conditions were: no treatment (open circles); 25 μ g/ml taurolidine (closed circles); 50 μ g/ml taurolidine (open squares); 100 μ g/ml taurolidine (closed

squares); and vehicle alone (closed triangles). Doubling times were determined under each condition, and expressed as a percentage of the rate of doubling of untreated cells. These values are located to the right of the growth curves in (Fig. 11B). Cells were subcultured when they reached a concentration of 6×10^5 cells/ml. Data are mean \pm SEM of three experiments.

Fig. 12A, Fig. 12B, Fig. 12C, and Fig. 12D are flow cytometric analyses depicting changes in cell morphology following taurolidine treatment. MM6 and PBMC were treated for three hours with taurolidine, and then treated and untreated control cells were processed for flow cytometry. Monocytes in PBMC samples were identified by staining with FITC-conjugated anti-CD14, and lymphocytes by FITC-conjugated anti-CD3 and PE-conjugated anti-CD19. Fig. 12A represents untreated MM6 cells; Fig. 12B represents MM6 cells treated with 50 $\mu\text{g/ml}$ taurolidine; Fig. 12C represents untreated PBMC; and Fig. 12D represents PBMC treated with 75 $\mu\text{g/ml}$ taurolidine. M=monocytes; L=lymphocytes.

Fig. 13 is an agarose gel depicting DNA fragmentation in response to taurolidine treatment as determined by assay procedures. MM6 cells were incubated with taurolidine or vehicle in RPMI+10%BCS for four hours. Cells were harvested and low molecular weight DNA extracted as described below. C=control cells without taurolidine or vehicle treatment; T=treated with 50 $\mu\text{g/ml}$ taurolidine; V=treated with vehicle alone; and MW=molecular weight markers.

Fig. 14A and Fig. 14B are terminal deoxytransferase-mediated deoxyuridine-triphosphate-biotin nick end labeling assay (TUNEL) analyses of control cells and taurolidine-treated PBMC, respectively. Cells were incubated with 100 $\mu\text{g/ml}$ taurolidine for six hours and processed for TUNEL analysis as given below. Parallel samples were stained with FITC-conjugated anti-CD14 and propidium iodide (PI) as described below. Ten thousand events were recorded per sample. TUNEL signal (x-axis) is a measure of DNA fragmentation, which FSC (y-axis) is related to cell size. TUNEL-negative lymphocytes are bounded by the rectangle R1, while TUNEL-negative monocytes (CD14 positive cells) are

bounded by the rectangle R2. The vertical line indicates demarcation between TUNEL-negative and TUNEL-positive cells. There were minimal numbers of PI-positive cells in the six hour samples (see Table IV).

Fig. 15A, 15B, and 15C depict TUNEL analysis of PBMC treated with taurolidine in whole blood, for control cells, taurolidine-treated cells, and anisomycin-treated cells, respectively. Cells were incubated with 500 $\mu\text{g/ml}$ taurolidine for 4 hours, resuspended in fresh medium, incubated for two hours further and processed for TUNEL analysis. Parallel samples were stained with FITC-conjugated anti-CD14 and PI as described herein. Ten thousand events were recorded per sample. TUNEL signal (x-axis) is a measure of DNA fragmentation, while FSC (y-axis) is related to cell size. TUNEL-negative lymphocytes are bounded by rectangle R 1, while TUNEL-negative monocytes (CD 14 positive cells) are bounded by rectangle R2. R3 bounds the TUNEL-positive population of cells. There were minimal numbers of PI-positive cells in 6 hour samples (see Table VI).

DETAILED DESCRIPTION

Taurolidine (taurolin; tauroline; 4,4'-methylenebis(perhydro-1,2,4-thiadiazin 1,1-dioxide) is disclosed for the first time as an agent for treating patients inflicted with monocytic and/or myeloid leukemias. Taurolidine is administered by injection in solution (intravenously or intraperitoneally) to afflicted patients in an amount effective to cause apoptosis of monocytic and/or myeloid cells. The cells involved in the monocytic or myeloid leukemia disease are thus attacked and die via apoptosis.

Taurolidine has been reported as a useful agent for other applications, and thus, *in vitro* and clinical data is available on its physiological effects, even though there are no previous reports on its use as an apoptosis-inducer in monocytes, granulocytes, or leukemia cells. No toxic effects on epithelial cells were reported after two hour treatment with 5 mg/ml taurolidine, (Gorman, et al., "Reduced adherence of microorganisms to human mucosal epithelial cells following treatment with taurolin, a novel antimicrobial agent," *J Appl Bacteriol* 62:315 (1987)), and previous studies on monocytes reported that taurolidine was apparently non-toxic since there was no increase in LDH release by cells after 24-hour taurolidine treatment. Bedrosian, et al., "Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells," *Cytokine* 3:568 (1991); Dofferhoff, et al., "The release of endotoxin from antibiotic-treated *Escherichia coli* and the production of tumour necrosis factor by human monocytes," *J Antimicrob Chemother* 31:373 (1991).

In previous reports on other applications of taurolidine, such as for an agent to address septicemia, plasma concentrations of taurolidine (or its initial metabolite) achieved in clinical use range from 20 to 100 µg/ml in septic patients or normal volunteers. Browne, M.K., "Pharmacological and clinical studies with taurolin." In *Taurolin, Ein Neues Konzept zur Antimikrobiellen Chemotherapie Chirurgischer Infektionen*, Brückner, W.L. and Pfirrmann, R.W. (eds), München-

Wien-Baltimore, Urban & Schwarzenberg, p. 3, 1985; Nitsche, et al.,
"Investigations of endotoxin inactivation in plasma. Preliminary results of a
controlled randomized study on taurolidine as a supplementary therapeutic agent in
septicemia." In *Emergency Surgery Trends, Techniques, Results. Proceedings of*
5 *the 7th International Congress of Emergency Surgery*, Schweiberer, L. and Eitel,
F. (eds), Munich, Zuckschwerdt, p.185, 1985). Taurolidine treatment in humans
has not been associated with toxicity, even when septic patients have received up to
20 grams for 2-5 consecutive days. Willatts, et al., "Effect of the antiendotoxic
agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled
10 double-blind trial," *Crit Care Med* 23:1033 (1995); Johnson, et al., "Tauroiin for
the prevention of parenteral nutrition related infection: antimicrobial activity and
long-term use," *Clin Nutrition* 12:365 (1993).

It has been found that concentrations of taurolidine in the range of 50 to 100
 $\mu\text{g/ml}$ induced apoptosis in 75% of peripheral blood monocytes incubated in
15 culture medium within six hours. Further, 100 $\mu\text{g/ml}$ taurolidine induced
apoptosis in 92% of granulocytes incubated in culture medium within six hours.
Preferred therapeutic dosages for treatment of leukemias are from about 10 to
about 500 mg/kg body weight. Most preferred is a dose that results in a 200
 $\mu\text{g/ml}$ concentration in the plasma, which is typically about 150 mg/kg body
20 weight.

Taurolidine can be administered intravenously or intraperitoneally. For
treatment of the various leukemias, an effective amount of taurolidine to cause
apoptosis of the affected cells is used and can be monitored by periodic tests on
samples of the patient's blood where cells can be observed for evidence of
25 apoptosis using any technique such as TUNEL analysis, DNA fragmentation, or
with other suitable markers of apoptosis.

In our studies, taurolidine was used in the form of a 2% w/v solution in a
vehicle containing 2% dextrose and 5% polyvinylpyrrolidone. A solution
consisting of the vehicle alone was obtained from Wallace Laboratories (Cranbury,

NJ) for the preparation of a vehicle control. Reagents and supplies were obtained as follows: Histopaque, propidium iodide (PI), Lactate Dehydrogenase (LDH) Kit, rabbit brain thromboplastin, anisomycin, and dimethylsulfoxide (DMSO) from Sigma Chemical Co. (St. Louis, MO); 6% dextran 70 in 0.9% NaCl (6% dextran) from McGaw, Inc. (Irvine, CA); RPMI, Eagle's minimum essential medium (MEM), and Hank's balanced salt solution (HBSS) from Mediatech, Inc. (Herdon, VA); medium M199 from BioWhittaker, Inc., (Walkersville, MD); bovine calf serum (BCS) from HyClone Laboratories, Inc. (Logan, UT); 25% human serum albumin (HSA) from the American Red Cross Blood Services (Washington, D.C.); AIM-V medium from Gibco BRL (Grand Island, NY); LPS (*E. coli* 0111:B4) and bovine serum albumin (fatty acid free) from Calbiochem Corp. (La Jolla, CA); FITC-conjugated anti-CD14 antibodies, FITC-conjugated anti-CD3/PE-conjugated anti-CD19 Simultest, and PE-conjugated anti-CD16 from Becton Dickinson (Parsippany, NJ); and the TUNEL assay system (In Situ Cell Death Detection Kit) from Boehringer Mannheim (Indianapolis, IN).

Numerous cell lines have been examined and are listed in Table I. MM6 cells, derived from the peripheral blood of a patient with acute monoblastic leukemia (M5), were a generous gift of Dr. H. Ziegler Heitbrock. The K562 cell line, developed from cells from pleural fluid of a patient with chronic myeloid leukemia in blast crisis, was obtained from the American Type Culture Collection (ATCC) (Rockville, MD). K562 cells can be induced to differentiate into precursors of the monocytic, granulocytic, and erythrocytic series. HL-60 cells, established from peripheral blood leukocytes of a patient with acute promyelocytic leukemia, were obtained from ATCC. HL-60 cells display surface receptors and react with cytochemical stains specific for granulocytic cells. REH cells, originated from acute lymphoblastic leukemia cells, were obtained from ATCC. REH cells have a non-T, non-B phenotype. Jurkat is a human leukemic T cell line available from ATCC. ECV304, a spontaneously transformed immortal endothelial cell line derived from a human umbilical cord, was obtained from

Table I. Cell Lines Tested

| Human Cell Line | Derived from a Patient with |
|-----------------|------------------------------------------------------------|
| HL-60 | acute myeloid leukemia |
| K-562 | chronic myelogenous leukemia |
| Mono Mac 6 | monocytic leukemia |
| REH | acute lymphocytic leukemia |
| Jurkat | human leukemic T cell line |
| ECV304 | human endothelial cell line (spontaneously transformed) |
| GM5387 | human fetal fibroblast cell line |

ATCC. The human fibroblast cell line GM5387, derived from tissue obtained by fetal lung biopsy, was obtained from NIGMS Human Genetic Mutant Cell Repository.

All cells were cultured in a 5% CO₂ atmosphere at 37°C. MM6 cells were grown in RPMI supplemented with 10% BCS, 2 mM L-glutamine, and 50 µg/ml gentamicin (RPMI + 10% BCS). In some experiments, MM6 cells were rinsed once with HBSS without Ca⁺⁺ or Mg⁺⁺ and once with AIM-V before finally being resuspended in AIM-V supplemented with 0.01% BCS (AIM-V + 0.01% BCS).

AIM-V has been shown to support long-term culture of macrophages (Helsinki, et al., "Long-term cultivation of functional human macrophages in teflon dishes with serum-free media," *J Leuk Biol* 44:111 (1988)), and in the present experiments, MM6 cells cultured in AIM-V for at least ten days maintained high viability and exhibited growth rates only slightly slower than cells grown in RPMI supplemented with 10% BCS. AIM-V was supplemented with a low amount of BCS (0.01%) in order to provide a source of LPS-binding protein, which enhances the response of monocytic cells to LPS. Ulevitch, R.J. and Tobias, P.S., "Recognition of endotoxin by cells leading to transmembrane signaling," *Curr Opin Immunol* 6:125 (1994). HL-60, REH, and Jurkat were cultured in RPMI supplemented with 10%

heat inactivated fetal bovine serum (FBS), 2 mM L-glutamine, and 50 μ g/ml gentamicin. ECV304 were cultured in M199 supplemented with 10% FBS, mM L-glutamine, and 50 μ g/ml gentamicin. GM5387 was cultured in MEM supplemented with 20% FBS, 2 mM L-glutamine, and 50 μ g/ml gentamicin.

5 Human peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood by centrifugation using Histopaque as per manufacturer's instructions. The isolated PBMC were suspended in RPMI supplemented with 10% BCS and were used in experiments immediately thereafter. As determined by flow cytometry, PBMC were typically $11 \pm 2\%$ monocytes and $80 \pm 13\%$
10 lymphocytes, with the remaining cytometric events consistent in size with platelets and cell aggregates.

Human granulocytes were isolated from heparinized blood by diluting blood 1:1 with 6% dextran to sediment RBC, then centrifuging to obtain leukocyte rich plasma. The remaining RBC were lysed by 20 second incubation with 0.2%
15 NaCl. After lysis, NaCl was added to a final concentration of 0.9%, the sample was centrifuged, and the cell pellet resuspended in HBSS containing 0.5% HSA. An equal volume of Histopaque (Sigma) was layered underneath the cell suspension. Upon centrifugation, the PBMC remained above the Histopaque layer, while the granulocytes were sedimented. Purity of collected granulocytes was-
20 assayed by flow cytometry using PE-conjugated anti-CD19.

Tissue factor and TNF α expression

The induction of tissue factor (TF) expression by bacterial LPS was demonstrated in numerous cell lines including human peripheral blood mononuclear cells, human monocytic cell line Mono Mac 6 (MM6), and
25 granulocytes. The induction of tissue factor expression was blocked by treatment with taurolidine.

For induction of TF or TNF α expression, MM6 cells or PBMC were cultured either in RPMI supplemented with 10% BCS or in AIM-V + 0.01% BCS, and stimulated by adding LPS to final concentrations of 10 to 100 ng/ml. Cells

treated with taurolidine received final concentrations of 10 to 100 $\mu\text{g/ml}$ taurolidine, with parallel cultures receiving either no taurolidine or a comparable dilution of the vehicle alone. Except as noted, taurolidine and LPS were added to the cell cultures simultaneously. For TF determination, cells and culture media
5 together were treated by adding Triton X-100 (1% final) and EDTA (7 mmol/L final), and the resulting lysates assayed by ELISA. Rezaie, A.R., et al., "Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody," *Protein Expression and Purification* 3:453 (1992). For $\text{TNF}\alpha$ determination, cells were removed by
10 centrifugation for 5 min at 250 x g, and the supernatants were assayed by ELISA. Houston, et al., "Endothelial cells and extracellular calmodulin inhibit monocyte tumor necrosis factor release and augment neutrophil elastase release," *J Biol Chem* 272:11778-11785 (1997). In order to examine if taurolidine interfered with ELISA measurement of TF, taurolidine was added to lysates of cells that had
15 previously not been treated with the drug. Taurolidine had no effect on the measurement of TF levels.

A number of previous studies have shown that peripheral blood monocytes respond to LPS stimulation by expressing TF, with maximal expression typically occurring four to six hours after LPS treatment. Schwartz, et al, "Murine lymphoid
20 procoagulant activity induced by bacterial lipopolysaccharide and immune complexes is a monocyte prothrombinase," *J Exp Med* 155:1464 (1982); Gregory, et al., "Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin," *Mol Cell Biol* 9:2752 (1989). Furthermore, monocytes are the only cell type present in PBMC preparations that are capable of expressing TF.
25 When cultured in AIM-V + 0.01% BCS, MM6 cells and PBMC responded in a similar fashion to LPS stimulation (Fig. 1). For MM6 cells, maximal TF expression was achieved with 10 ng/ml LPS, resulting in an 11-fold induction of TF expression compared to unstimulated cells. For PBMC, maximal TF expression was > 30-fold higher than in unstimulated cells. When MM6 cells were

cultured in RPMI + 10% BCS, similar time courses of LPS-induced TF expression were observed, although maximal induction of TF expression was achieved with 100 ng/ml LPS, resulting in a 4.3-fold induction of TF expression compared to unstimulated cells.

5 The ability of taurolidine to inhibit LPS-induced TF expression in MM6 and PBMC was examined. Taurolidine at concentrations of 50 µg/ml or higher completely blocked the induction of TF expression in MM6 cells by LPS, while vehicle alone (used at a dilution comparable that of 100 µg/ml taurolidine) had no effect (Fig. 2A). Lower concentrations of taurolidine (10 or 25 µg/ml) had little or
10 no effect on TF expression by MM6 cells. TF expression by LPS-stimulated PBMC was also inhibited by taurolidine (Fig 2B), although slightly higher concentrations were required (i.e., 75 µg/ml taurolidine was required for complete inhibition of TF expression, compared with 50 µg/ml for MM6 cells). Taurolidine exhibited similar effectiveness in blocking TF expression when MM6 cells or
15 PBMC were cultured in either RPMI + 10% BCS or in AIM-V + 0.01% BCS.

Some of the immunomodulatory effects of taurolidine have been proposed to result from its breakdown product, taurine. William, et al., "Taurolidine, an antilipopolysaccharide agent, has immunoregulatory properties that are mediated by the amino acid taurine," *J Leuk Biol* 58:299 (1995). Therefore, in order to
20 examine this potential mechanism of action of taurolidine, we performed experiments as above using taurine at 44 µg/ml (equivalent in molar concentration to that which would be generated from the complete breakdown of 50 µg/ml taurolidine) and higher. Taurine had no effect on TF expression by MM6 cells, even at concentrations up to 0.5 mg/ml. Another proposed mechanism of action of
25 taurolidine is via direct inactivation of LPS. Pfirmann, R.W., "Taurolin: ein neues konzept zur antimikrobiellen chemotherapie chirurgischer infektionen einföhrung und übersicht." In *Taurolin, Ein Neues Konzept zur Antimikrobiellen Chemotherapie Chirurgischer Infektionen*, Brückner, W.L. and Pfirmann, R.W. (eds), München-Wien-Baltimore, Urban & Schwarzenberg, p. 3, 1985.

Accordingly, whether or not pre-incubation of cells with taurolidine would affect their subsequent response to LPS stimulation was examined. Similar reductions in TF expression were observed when cells were pre-exposed to 100 µg/ml taurolidine for thirty minutes, rinsed, and then exposed to LPS, compared to
5 experiments in which taurolidine and LPS were added concurrently. Thus, direct contact between taurolidine and LPS was not necessary for taurolidine to block the subsequent induction of TF expression by LPS.

Taurolidine inhibited LPS-induced secretion of TNFα by MM6 cells and PBMC (Fig. 3). MM6 cells were slightly more sensitive to taurolidine, since
10 maximal inhibition was obtained with 75 µg/ml taurolidine, while 100 µg/ml taurolidine was required to maximally inhibit TNFα secretion by PBMC. For MM6 cells, the concentration-dependence of taurolidine inhibition was biphasic, with high concentrations strongly inhibiting TNFα expression and intermediate concentrations (most particularly, 25 µg/ml) markedly stimulating TNFα secretion.
15 Taurine at 44 µg/ml had no effect on TNFα expression by MM6 cells.

Treating peripheral blood monocytes or cultured MM6 cells with taurolidine strongly inhibited the induction of TF in response to LPS. Expression of TF is an important effector function of activated monocytes in sepsis and, in particular, previous studies have shown that blocking antibodies to TF can protect
20 baboons from the lethal effects of intravenous *E. coli* in an animal model of gram-negative septic shock (Taylor, et al., "Lethal *E. coli* septic shock is prevented by blocking tissue factor with monoclonal antibody," *Circ Shock* 33:127 (1991)) and can attenuate the coagulopathy associated with LPS injection into chimpanzees (Levi, et al, "Inhibition of endotoxin-induced activation of coagulation and
25 fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees," *J Clin Invest* 93:114 (1994)). Therefore, the ability of taurolidine to block the induction of TF in monocytes is an important aspect of its clinical efficacy in treating sepsis.

In order to determine if taurolidine would inhibit LPS-induced TF expression in PBMC in their native milieu, i.e., whole blood, a tissue factor activity assay was performed. LPS (10 ng/ml) and taurolidine (100-500 μ g/ml) or equal dilutions of the taurolidine vehicle were added to 5 ml aliquots of heparinized blood, and the blood was incubated in 50 ml centrifuge tubes at 37°C, rotating on a horizontal rotator at 120 rpm. After 4 hours, PBMC were purified from the blood using Histopaque as described previously. Cells were lysed by 3 freeze-thaw cycles, and used as a source of TF in coagulation assays. For these assays, 50 μ l of lysate (at 2×10^7 cells/ml) was added to 50 μ l pooled normal human plasma, incubated for 30 seconds at 37°C, then 50 μ l of 25 mM CaCl_2 was added and clot formation assayed using a Diagnostica Stago ST4 coagulometer. Protein content of the cell samples was determined by bicinchoninic acid assay (Pierce Chemical Company, Rockford, IL), and used to normalize the clotting data. A standard curve was made with dscytoTF reconstituted in PS/PC vesicles according to the method of Mimms et al. (Mimms, et al., "Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside," *Biochemistry* 20:833-840 (1981)). One unit of TF was defined as that which caused clot formation at 50 seconds of incubation with CaCl_2 . The TF activity assays were performed on LPS-induced PBMC after 4 hour treatment in whole blood. A dose-response effect of taurolidine on monocyte TF is illustrated in Table II. Taurolidine at 100 μ g/ml decreased TF activity by 12%; 200 μ g/ml decreased activity by approximately 60%, and treatment with 500 μ g/ml taurolidine resulted in loss of approximately 75% of TF activity. Thus, higher concentrations of taurolidine were required to inhibit TF when the PBMC were treated with whole blood when compared to PBMC in culture medium. Further, lower concentrations of taurolidine were required to down-regulate TF expression than were needed to induce apoptosis as described below.

In addition to its role in the pathology of sepsis, TF expression on the surface of leukemia cells (especially acute myelogenous leukemias (AML) and

Table II. Effect of Taurolidine Treatment on Coagulation

Activity of LPS-induced PBMC

| Treatment | % of control ^a |
|--------------------------|---------------------------|
| control | 100 |
| vehicle | 123.5 ± 29.0 |
| 100 µg/ml taurolidine | 87.7 ± 6.6 |
| 200 µg/ml taurolidine | 41.7 ± 8.0 |
| 500 µg/ml taurolidine | 26.5 ± 10.6 |

^a Heparinized blood was incubated in the presence of LPS and varying amounts of taurolidine, then PBMC were purified, and coagulation assays performed on cell lysates. Units of TF per mg protein were calculated as described above, and data expressed as percentage of LPS-only ("control") samples. Data shown are mean ± S.D. of two experiments.

acute lymphoblastic leukemias (ALL) is associated with severe coagulopathies in leukemic patients (Bauer, et al., "Tissue factor gene expression in acute myeloblastic leukemia," *Thromb Res* 56:425-430 (1989); Hair, et al., "Tissue factor expression in human leukemia cells," *Leuk Res* 20:1-11 (1996); and Tanaka, M. and Yamanishi, H., "The expression of tissue factor antigen and activity on the surface of leukemic cells," *Leuk Res* 17:103-111 (1993). These coagulopathies can include life-threatening thrombotic and bleeding episodes, as well as the development of disseminated intravascular coagulation (DIC). Furthermore, episodes of thrombosis and DIC in such leukemic patients can be induced by chemotherapy. Therefore, the ability of taurolidine to reduce expression of TF by leukemic cells (exemplified by the MM6 cell line) should be beneficial in reducing

the incidence and severity of coagulopathies in leukemic patients, even at doses which do not kill the leukemia cells.

Effect of taurolidine on cell viability and growth rates

Apoptosis is a controlled form of cell death characterized by the fact that
5 neither parent cells nor apoptotic bodies become membrane-permeable. This characteristic distinguishes apoptosis from necrosis wherein cell death involves rupture of cell membranes. Assessment of apoptosis was performed by determining the cell membrane integrity of various cell lines, continued long-term culture of cells after taurolidine treatment to determine growth rate, and membrane
10 permeability after taurolidine treatment. It was found that taurolidine causes apoptosis rather than necrosis of leukemia cells.

In these experiments, integrity of cell membranes following taurolidine treatment was assessed by exclusion of trypan blue and by measuring the release of LDH in MM6, K-562, HL-60, and REH cells. Since BCS contains significant
15 amounts of LDH, these experiments were conducted on cells cultured in AIM-V + 0.01% BCS. Four hour treatment of cells was conducted in AIM-V containing 0.01 % BCS in order to allow subsequent LDH assay without interference from BCS (which occurs in when normal culture medium, containing 10% BCS, is used). Thus, MM6 cells (5×10^5 cells/ml) were treated with taurolidine for four
20 hours in AIM-V + 0.01% BCS, after which an aliquot of the cell suspension was removed for measurement of LDH release. A parallel aliquot of cells was lysed by three cycles of freeze/thaw and the quantity of LDH released was taken to be 100%. Remaining cells were rinsed in HBSS and resuspended in growth medium for measurement of growth rates.

25 Upon microscopic examination of MM6 cultures treated for four hours with 100 µg/ml taurolidine, the cells appeared to be smaller than control cells and the cultures were observed to contain numerous small, spherical bodies which excluded trypan blue. In one study, the integrity of the cell membrane was assessed by measurement of LDH release in PBMC and MM6 cells cultured in

AIM-V + 0.01% BCS. After treatment with 0 to 50 $\mu\text{g/ml}$ taurolidine for four hours, LDH levels in the treated cultures ranged from 6 to 9% of that of freeze/thaw lysed cells (mean values of three separate experiments), which was not significantly different from LDH levels in cultures not treated with taurolidine.

- 5 Additionally, after four hour treatment, control and taurolidine-treated cells were equally able to exclude trypan blue (Fig 4A, Day 1). However, when taurolidine-treated MM6 cells were rinsed and resuspended in growth medium, 65% of cells exposed to 50 $\mu\text{g/ml}$ taurolidine became trypan blue-positive on the day following treatment (Fig. 4A, Day 2), indicating that the plasma membrane had become
- 10 permeable. In contrast, only 5% of untreated ("control") and vehicle-treated cells were trypan blue-positive. Cells treated with 50 $\mu\text{g/ml}$ taurolidine for four hours failed to grow when returned to growth medium, while cells treated with vehicle alone or with 25 $\mu\text{g/ml}$ taurolidine exhibited growth rates similar to that observed with untreated cells (Fig 4B). In another study, K-562, HL-60, and REH cells were
- 15 tested after a four hour treatment with taurolidine, and the results are summarized in Table III.

- HL-60 cells treated with 50 $\mu\text{g/ml}$ taurolidine. In these samples, LDH present in the culture medium was $8.3 \pm 2.3\%$ of that released by completely lysed cells, compared with $2.3 \pm 0.8\%$ measured in control cultures. All samples from
- 20 all other cell lines displayed LDH levels which were $\leq 7\%$ of lysed cell samples ($n=3$). After 4 hour treatment, cells were rinsed and returned to growth medium and monitored for viability and growth over the following 3 days. Concentrations of taurolidine from 25 $\mu\text{g/ml}$ to 100 $\mu\text{g/ml}$ were used in order to highlight differences in sensitivity of cell lines to taurolidine. Trypan blue assay of all
- 25 samples were equivalent to control on Day 1 (after 4 hours of treatment) indicating that taurolidine treatment did not cause rapid permeability of cell membranes, suggesting that this compound did not cause cellular necrosis. However, over the following days, all leukemia-derived-cell lines demonstrated progressive

Table III. Results from a Four Hour Treatment with Taurolidine

| Cell Type | Conc. Taurolidine | LDH (% of total) ^a | growth rate (% of control) ^b |
|-----------------------------------------------|-------------------|-------------------------------|-----------------------------------------|
| K-562 (chronic myelogenous leukemia) | control | 8 | 100 |
| | 50 μ g/ml | 6 | 52 |
| | 100 μ g/ml | 8 | 0 |
| | vehicle | 6 | 80 |
| HL-60 (acute myeloid leukemia) | control | 5 | 100 |
| | 50 μ g/ml | 5 | 0 |
| | 100 μ g/ml | 6 | 3 |
| | vehicle | 4 | 92 |
| REH (acute lymphocytic leukemia) | control | 4 | 100 |
| | 50 μ g/ml | 6 | 1 |
| | 100 μ g/ml | 5 | 18 |
| | vehicle | 5 | 119 |

^a LDH was measured immediately after four hour taurolidine treatment.

^b Growth rate was measured over three days following treatment.

permeability to trypan blue after treatment with concentrations of taurolidine of 50 μ g/ml or greater, with the exception of K562 cells (Fig. 5A, 6A, 7A, 8A, and 9A). MM6, K562, and Jurkat cells did not show an increase in trypan blue staining after treatment with 25 μ g/ml taurolidine, while HL-60 and REH cells were more sensitive. As explained, eventual permeability of cell membranes is inevitable in in vitro apoptosis. K562 cells demonstrated an inhibition of growth after taurolidine treatment of 50 μ g/ml or greater as did the other leukemia-derived cell lines (Fig. 5B, 6B, 7B, 8B, and 9B). Cell lines demonstrated differing sensitivities to taurolidine in regard to cell growth, with K562 and Jurkat cells being least affected, and HL-60 growth being most inhibited after taurolidine treatment.

The adherent cell lines ECV304 (endothelial cells) and GM5387 (fibroblasts) did not demonstrate a significant increase in trypan blue staining of

cells during 4 day growth after taurolidine treatment (Fig. 10A and 11A). However, proliferation of these cells was inhibited after treatment with 50 and 100 $\mu\text{g/ml}$ taurolidine (Fig. 10B and 11B).

Detection of apoptosis

5 The effect of taurolidine on cell lines of various lineages with respect to apoptosis was evaluated. Treatment with effective amounts of taurolidine resulted in apoptosis in a variety of monocytic, granulocytic and numerous leukemic cell lines, but not in lymphocytes.

 Following treatment with either taurolidine or the vehicle solution, cell
10 death was assessed in one of two ways. In the first method, the DNA fragmentation pattern characteristic of apoptosis was detected by extracting low molecular weight DNA from cells using a phosphate-citrate buffer (Darzynkiewicz, et al., "Assays of cell viability: discrimination of cells dying by apoptosis," *Methods Cell Biol* 41:15 (1994)) and subjecting the extracted DNA to agarose gel
15 electrophoresis.

 In the second method, DNA fragmentation was detected via TUNEL assay according to the manufacturer's instructions. With this methodology, 2×10^6 cells were fixed with 2% paraformaldehyde, permeabilized with 0.1% Triton X-100/0.1% citrate, incubated at 37°C with terminal deoxynucleotidyl transferase and
20 FITC-dUTP, rinsed and analyzed by flow cytometry. Enhanced FITC signal indicates apoptosis-specific DNA fragmentation. Gavriali, et al, "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation," *J Cell Biol* 119:493 (1992). Parallel aliquots of unfixed cells were treated with PI and FITC-conjugated anti-CD14 and analyzed by flow cytometry, in order to
25 identify cells with permeable cell membranes (since PI binds to DNA but is excluded from cells with intact plasma membranes) and also to determine the cell-specificity of the apoptotic signal.

 A Becton-Dickinson FACSCalibur instrument was used for flow cytometric analysis of cells. Assessment of cell diameter (forward scatter; FCS) and

granularity (side scatter; SSC) was carried out on unfixed cells. Discrimination between lymphocytes and monocytes was made possible by their characteristic differences in FSC and SSC, and confirmed by staining monocytes with FITC-labeled anti-CD14 antibodies and lymphocytes with a combination of FITC-conjugated anti-CD3 and PE-conjugated anti-CD19. After incubation with taurolidine (with or without concomitant LPS treatment), cells were rinsed twice in phosphate-buffered saline containing 0.1% bovine serum albumin (PBSA) and 1×10^6 cells were resuspended in 0.1 ml PBSA. After 5 μ l FITC-conjugated anti-CD14 was added, cells were incubated in the dark on ice for 15 minutes and then centrifuged at 250 x g. Cells were resuspended in 500 μ l PBSA containing 5 μ g/ml PI and subjected to flow cytometry.

Taurolidine-treated MM6 cells and peripheral blood monocytes displayed reduced cell size as illustrated by a decrease in FSC and SSC when cells were analyzed by flow cytometry (Fig 12). After a three hour treatment with taurolidine, MM6 cells demonstrated an approximately 30% decrease in FSC, as did peripheral blood monocytes after a six hour treatment. These morphological changes (reduced cell size and appearance of spherical bodies) were concomitant with an intact plasma membrane, indicating that taurolidine induces apoptosis in monocytic cells.

Apoptosis is associated with fragmentation of genomic DNA in the internucleosomal linker regions, which can be visualized as a characteristic ladder of DNA fragments upon gel electrophoresis. Arends, M.J. and Wyllie, A.H., "Apoptosis: mechanisms and roles in pathology," *Int Rev Exp Path* 32:223 (1991). Accordingly, low molecular weight DNA was extracted from taurolidine-treated MM6 cells and subjected to electrophoresis in agarose gels. Cells treated with 50 μ g/ml taurolidine for four hours exhibited a prominent ladder pattern of DNA fragments, while untreated and vehicle-treated cells did not (Fig. 13). These cells had not been treated with LPS; however, identical results were seen when LPS was

present during taurolidine treatment. These results support the conclusion that taurolidine induces apoptosis in MM6 cells.

In order to examine if taurolidine treatment induced apoptosis in peripheral blood monocytes, a technique was employed for evaluating DNA fragmentation that could be applied to mixed populations of monocytes and lymphocytes. Consequently, TUNEL analysis was performed on PBMC at 3, 6, or 24 hours after treatment with 25 to 100 $\mu\text{g/ml}$ taurolidine. Aliquots of harvested cells were also labeled with FITC-conjugated anti-CD14 antibodies and PI, which allowed identification of monocytes (CD14-positive cells) and cells with damaged cell membranes (PI-positive cells). While relatively few of the PBMC were TUNEL-positive after a three hour incubation, a substantial population of TUNEL-positive cells was readily apparent after six hours of incubation with 100 $\mu\text{g/ml}$ taurolidine (events to the right of the vertical line in Fig. 14), concomitant with a large loss of TUNEL-negative monocytes (region R1 in Fig. 14; see also Table IV). Thus, nearly 75% of the monocytes were TUNEL-positive following treatment with 100 $\mu\text{g/ml}$ taurolidine for six hours. Confirmation that the TUNEL-positive cells were monocytes was obtained by staining with FITC-conjugated anti-CD14. Lower doses of taurolidine (25 and 50 $\mu\text{g/ml}$) resulted in lower levels of induction of apoptosis (Table IV). Taurolidine-treated and control cells exhibited equivalently low levels of PI-positive cells at six hours, indicating that the cell membranes remained intact at this time (Table IV). In another study summarized in Table V, taurolidine-treated polymorphonuclear cells (granulocytes) at 100 $\mu\text{g/ml}$, MM6 cells (monocytic leukemia cell line) at 50 $\mu\text{g/ml}$, and acute myeloid leukemia cell line (HL-60) at 50 $\mu\text{g/ml}$ exhibited a high level of apoptosis as indicated by the low percentage of % TUNEL-negative cells, and the low percentage of propidium iodide positive cells confirmed that the treated cells remained intact.

In contrast to its effect on monocytes, treatment with up to 100 $\mu\text{g/ml}$ taurolidine for six hours did not induce detectable apoptosis in the lymphocyte

Table IV. Dose-Response of PBMC to Taurolidine: 6 Hour Treatment^a

| Cell Type | Treatment | % Propidium Iodide Positive | % TUNEL-Negative ^b |
|-------------|-----------------------|-----------------------------|-------------------------------|
| All Cells | Control | 11.0 ± 1.6 | |
| | 25 µg/ml taurolidine | 9.0 ± 3.2 | |
| | 50 µg/ml taurolidine | 12.2 ± 5.6 | |
| | 100 µg/ml taurolidine | 9.0 ± 3.5 | |
| Monocytes | Control | | 100 |
| | 25 µg/ml taurolidine | | 88.3 ± 2.7 |
| | 50 µg/ml taurolidine | | 67.8 ± 18.0 |
| | 100 µg/ml taurolidine | | 25.1 ± 11.9 |
| Lymphocytes | Control | | 100 |
| | 25 µg/ml taurolidine | | 100.2 ± 7.0 |
| | 50 µg/ml taurolidine | | 99.8 ± 3.4 |
| | 100 µg/ml taurolidine | | 101.9 ± 3.1 |

^a Analysis by flow cytometry after staining cells with FITC-conjugated anti-CD14 and PI, and processing for TUNEL. Data are mean ± SD of two experiments.

^b Percent of cells present in the TUNEL-negative region in control samples.

population of PBMC, with essentially 100% of the cells remaining TUNEL-negative (Fig. 14 and Table IV).

Taurolidine at 100 µg/ml induced apoptosis of approximately 75% of purified peripheral blood monocytes when these cells were incubated in culture medium. However, in order to more closely mimic the milieu of leukocytes in vivo, induction of apoptosis in PBMC by taurolidine was studied in whole blood (anticoagulated with heparin). As before, apoptosis was quantitated by measuring the loss of monocytes from a TUNEL-negative (no DNA fragmentation), CD 14 positive population of cells which was concomitant with the appearance of a TUNEL-positive population of cells. Treatment of PBMC in whole blood resulted

Table V. Induction of Apoptosis by Taurolidine

| Cell Type | Conc. Taurolidine | Length of Incubation | % Propidium Iodide Positive Cells ^a | % TUNEL-Negative Cells ^b |
|---------------------------|-------------------|----------------------|------------------------------------------------|-------------------------------------|
| granulocytes ^c | control | 6 hours | 1 | 98 |
| | 100 μ g/ml | 6 hours | 2 | 8 |
| Mono Mac 6 ^d | control | 3 hours | 10 | 98 |
| | 50 μ g/ml | 3 hours | 7 | 44 |
| HL-60 ^e | control | 3 hours | 7 | 85 |
| | 50 μ g/ml | 3 hours | 5 | 35 |

^a Propidium iodide labels only those cells with leaky plasma membranes.

Apoptotic cells do not initially have leaky plasma membranes.

^b The TUNEL assay is used to identify cells with apoptosis-specific DNA fragmentation. TUNEL-negative cells are not apoptotic.

^c granulocytes (polymorphonuclear cells).

^d Monocytic leukemia cell line.

^e Acute myeloid leukemia cell line.

in a shift of the taurolidine dose-response curve. Concentrations of taurolidine up to 200 μ g/ml did not induce significant apoptosis when cells were treated in whole blood (Table VI and Fig. 15A). However, taurolidine at 500 μ g/ml resulted in the appearance of a population of TUNEL-positive cells (Fig. 15B, region 3), and loss of 70% of TUNEL-negative monocytes (Table VI). As a positive control for induction of apoptosis, some cells were treated with anisomycin, a protein synthesis inhibitor known to induce apoptosis in monocytes. Anisomycin treatment of PBMC in whole blood also resulted in a loss of TUNEL-negative monocytes; however, fewer TUNEL-positive cells were detected after 6 hour incubation (Fig. 15C, region 3). There was no evidence for a significant effect of either taurolidine or anisomycin on induction of apoptosis in lymphocytes.

Table VI. Dose-response of PBMC (in whole blood) to Taurolidine^a

| Treatment | % propidium iodide | % TUNEL-negative ^b |
|-----------------------|--------------------|-------------------------------|
| All cells | | |
| control | 1.4 ± 0.6 | |
| 200 µg/ml taurolidine | 1.6 ± 0.6 | |
| 500 µg/ml taurolidine | 1.4 ± 0.2 | |
| Monocytes | | |
| control | | 100 |
| 200 µg/ml taurolidine | | 117.4 ± 11.2 |
| 500 µg/ml taurolidine | | 27.9 ± 12.0 |
| Lymphocytes | | |
| control | | 100 |
| 200 µg/ml taurolidine | | 92.7 ± 6.0 |
| 500 µg/ml taurolidine | | 91.8 ± 6.9 |

^a Analysis by flow cytometry after staining cells with PI and processing for TUNEL. Data are mean ± SD of 2 experiments.

^b Percent of cells present in the TUNEL-negative region in control samples.

The effect of taurolidine on granulocytes was assayed by TUNEL analysis on taurolidine-treated purified granulocytes. These experiments were conducted in culture medium rather than whole blood. Granulocytes were treated with 100 µg/ml taurolidine since it had been shown that this concentration of taurolidine is apoptogenic to peripheral blood monocytes treated in culture medium. TUNEL-positive granulocytes ranged from 2% to 30% in untreated samples, and varied according to blood donor. Taurolidine treatment resulted in apoptosis of 92% of the granulocytes within 6 hours (Table VII). Therefore, the apoptogenic effect of taurolidine is not specific to monocytic cells.

Table VII. Response of Granulocytes to 100 $\mu\text{g/ml}$ Taurolidine ^a.

| | % propidium iodide positive | % TUNEL-positive |
|--------------|--------------------------------|------------------|
| granulocytes | | |
| control | 0.5 ± 0.2 | 17.0 ± 7.0 |
| taurolidine | 1.6 ± 0.5 | 91.5 ± 3.5 |
| vehicle | 0.5 ± 0.2 | 17.5 ± 7.0 |

^a Analysis by flow cytometry after staining cells with PI and processing for TUNEL. Data are mean \pm SEM of 5 experiments.

10

In another study, TUNEL assays were performed on all cell lines 6 hours after cells were initially exposed to taurolidine (cells were treated for 4 hours, rinsed, and then incubated for 2 more hours before TUNEL assay was performed). For these experiments, the effect of 100 $\mu\text{g/ml}$ taurolidine was compared to that of 1 $\mu\text{g/ml}$ anisomycin, a protein synthesis inhibitor demonstrated to induce apoptosis in monocytic (Kochi, S.K. and Collier, R. J., "DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis," *Exp Cell Res* 208:296-302 (1993)), granulocytic (Polverio, A.J. and Patterson, S.D., "Selective activation of caspases during apoptotic induction in HL-60 cells," *J Biol Chem* 272:7013-7021 (1997)), and epithelial (Liao, et al., "Stress, apoptosis, and mitosis induce phosphorylation of human keratin 8 at Ser-73 in tissues and cultured cells," *J Biol Chem* 272:17565-17573 (1997)) cell lines. Taurolidine and anisomycin induced apoptosis in MM6, HL-60, and Jurkat cells (Table VIII). MM6 and HL-60 cells were similarly effected, with >80% TUNEL-positive cells after 6 hours. Jurkat cells were less sensitive, with approximately 50% of cells induced to undergo apoptosis after taurolidine treatment. After 6 hours, 73% of anisomycin-treated REH cells were apoptotic, with less than 20% of taurolidine-treated REH cells being TUNEL-positive. However, assay of cells 24 hours after

25

Table VIII. Response of Cell Lines to Taurolidine and Anisomycin

| Cell line | % propidium iodide positive | % TUNEL-positive |
|---------------------|-----------------------------|------------------|
| MM6 | | |
| control | 7.3 ± 0.5 | 3.6 ± 2.6 |
| 5 taurolidine | 22.4 ± 0.8 | 80.9 ± 7.7 |
| aniso | 19.1 ± 5.4 | 92.0 ± 2.3 |
| K562 | | |
| control | 2.2 ± 0.1 | 0.6 ± 0.2 |
| 10 taurolidine | 2.2 ± 0.8 | 6.6 ± 2.8 |
| aniso | 4.8 ± 3.1 | 8.5 ± 8.8 |
| HL-60 | | |
| control | 3.7 ± 3.2 | 2.4 ± 0.6 |
| 15 taurolidine | 9.1 ± 8.2 | 91.9 ± 10.9 |
| aniso | 28.3 ± 15.3 | 96.1 ± 6.8 |
| REH | | |
| 15 control | 2.5 ± 0.6 | 2.8 ± 1.0 |
| taurolidine | 4.4 ± 1.6 | 18.3 ± 10.7 |
| aniso | 18.4 ± 0.5 | 72.9 ± 7.4 |
| Jurkat | | |
| 20 control | 3.6 ± 0.3 | 0.6 ± 0.2 |
| taurolidine | 6.1 ± 5.8 | 51.7 ± 1.4 |
| aniso | 5.1 ± 3.4 | 69.6 ± 19.8 |
| ECV304 | | |
| 25 control | 5.6 ± 0.7 | 0.0 ± 0.0 |
| taurolidine | 2.0 ± 1.4 | 0.0 ± 0.0 |
| aniso | 2.2 ± 3.1 | 0.0 ± 0.0 |

| Cell line | % propidium iodide positive | % TUNEL-positive |
|-------------|-----------------------------|------------------|
| GM5387 | | |
| control | 5.7 \pm 2.1 | 0.0 \pm 0.0 |
| taurolidine | 5.9 \pm 1.8 | 0.0 \pm 0.0 |
| anisomycin | 5.4 \pm 3.2 | 0.0 \pm 0.0 |

* Analysis by flow cytometry after staining cells with propidium iodide and processing for TUNEL. Data are percent of total cell-sized events, and are expressed as mean \pm SD of two experiments. Cells were treated for 4 hours with taurolidine (100 μ g/ml) or anisomycin (1 μ g/ml), and then assayed at 6 hours.

treatment indicated that taurolidine does induce apoptosis in REH cells (Table IX), but that it occurs less rapidly than with anisomycin treatment, suggesting that these two agents may work by different mechanisms. K562 cells were the most resistant to apoptosis, with less than 10% TUNEL-positive cells 6 hours after treatment with either anisomycin or taurolidine. Some induction of apoptosis was demonstrated after 24 hours, with approximately 20% of taurolidine-treated K562 becoming TUNEL-positive.

Less than 0.1 % of ECV304 or GM5387 cells were TUNEL-positive 6 hours after treatment with taurolidine or anisomycin (Table VIII). Therefore, neither of these agents induce rapid DNA fragmentation in these cell types. However, there was approximately a 70% increase in the number of subcellular-sized events recorded by flow cytometry after taurolidine treatment of these cells, indicating some effect of taurolidine on cell integrity. These cell fragments were not stained by propidium iodide, consistent with them being apoptotic bodies.

In summary, concentrations of taurolidine that were effective in inhibiting the induction of TF and TNF α expression in LPS-stimulated monocytic cells were also effective in inducing apoptosis in these cells. This was established by agarose gel electrophoretic analysis of DNA fragmentation MM6 cells and by TUNEL

Table IX. Response of Cell Lines to Taurolidine and Anisomycin:
Apoptosis at 24 hours After Treatment^a

| Cell line | % propidium iodide | % TUNEL positive |
|-------------|--------------------|------------------|
| K562 | | |
| control | 2.2 ± 0.3 | 0.5 ± 0.2 |
| taurolidine | 12.4 ± 2.1 | 21.2 ± 14.6 |
| anisomycin | 7.1 ± 2.3 | 2.2 ± 6.2 |
| REH | | |
| control | 3.6 ± 0.2 | 1.7 ± 1.8 |
| taurolidine | 55.8 ± 19.9 | 81.4 ± 4.4 |
| anisomycin | 51.6 ± 17.0 | 53.0 ± 2.6 |

^a Analysis by flow cytometry after staining cells with propidium iodide and processing for TUNEL. Data are percent of total cell-sized events, and are expressed as mean ± SD of two experiments. Cells were treated for 4 hours with taurolidine (100 µg/ml) or anisomycin (1 µg/ml), and then assayed at 24 hours.

analysis of peripheral blood monocytes. Induction of apoptosis was relatively rapid, being detectable within four to six hours after treatment in MM6 cells and monocytes. In this time frame, DNA fragmentation was readily detectable in cells whose plasma membranes were still intact. Eventually, however, cell permeability increased (e.g., 24 hours after treatment with taurolidine). This is likely to be due to "secondary necrosis," an inevitable result of advanced *in vitro* apoptosis where there is no system for phagocytosis and intracellular degradation of apoptotic cells. It has now been found that taurolidine also induces apoptosis of monocytic cells treated in whole blood. The effective concentration (500 µg/ml) is 5 times that required when purified PBMC are treated in culture medium. It has been proposed that metabolites of taurolidine inactivate LPS and kills bacteria by forming cross-

links between primary amine and hydroxyl groups on LPS and bacterial cell walls. (Browne, et al., "Taurolin, a new chemotherapeutic agent," *J Appl Bacteriol* 41:363-368 (1976); Pfirrmann, R.W., "Taurolin: ein neues konzept zur antimikrobiellen chemotherapie chirurgischer infektionen einfuhrung und
5 ubersicht," In: *Taurolin, ein neues konzept zur antimikrobiellen chemotherapie chirurgischer infektionen*, edited by Brückner, W.L. and Pfirrmann, R.W., München-Wien-Baltimore: Urban and Schwarzenburg; pp. 3-23 (1985)). If taurolidine induces apoptosis by similar mechanisms, incubation in whole blood could reduce its effectiveness by providing a high concentration of non-cellular
10 substrates. In fact, taurolidine has been reported to react with proteins in plasma and serum (Jones, et al., "A study of the stability of taurolidine in plasma and protein-free serum," *Int J Pharm* 64:R1-R4 (1990)). Taurolidine also reduces the TF activity of LPS-induced monocytes treated in whole blood, with significant reduction seen with concentrations of taurolidine as low as 200 $\mu\text{g/ml}$.

15 Taurolidine does not induce a significant amount of apoptosis in lymphocytes even at concentrations (in whole blood) up to 500 $\mu\text{g/ml}$. However, taurolidine is at least as effective in inducing apoptosis in granulocytes as it is in monocytes, as measured by TUNEL assays performed on purified cells treated in culture medium. It has been reported that both granulocytes and monocytes, but
20 only a fraction of lymphocytes, constitutively express Fas antigen (Iwai, et al., "Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils," *Blood* 84:1201-1208 (1994)), and that cross-linking of the cell surface Fas mediates transduction of apoptotic signals into cells (Itoh, et al., "The polypeptide encoded by the cDNA
25 for human cell surface antigen Fas can mediate apoptosis," *Cell* 66:233-243 (1991)). Although the mechanism by which taurolidine induces apoptosis is unknown, taurolidine affects monocytes and granulocytes but not lymphocytes.

Specificity of taurolidine's ability to induce apoptosis was further investigated by assessing its effects on a variety of leukemic cell lines. Taurolidine

was most effective in inducing apoptosis in monocytic (MM6) and granulocytic (HL-60) leukemic cell lines, analogous to its potent effect on peripheral blood monocytes and granulocytes. However, taurolidine was also able to induce apoptosis in a significant proportion of Jurkat cells, a lymphocytic leukemia cell line. Approximately 50% of these cells became apoptotic within 6 hours of treatment. Taurolidine did not induce apoptosis in peripheral blood lymphocytes under similar experimental conditions, indicating that leukemia-derived cells may be more sensitive to taurolidine than normal cells. Taurolidine was also able to induce apoptosis in the lymphoblastic cell line REH, although the process in these cells was delayed as compared to MM6 and HL-60.

As noted in previous studies (Evans, et al., "Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells," *Cancer Res* 53:1735-1738 (1993)), the multipotential cell line K562 was relatively resistant to apoptosis. Anisomycin induced less than 10% of these cells to become TUNEL-positive. Taurolidine was somewhat more potent, with approximately 20% of the cells becoming TUNEL-positive 24 hours after treatment was begun.

Although taurolidine inhibited proliferation of the endothelial and fibroblast cell lines, strong evidence for induction of apoptosis in these cells was not obtained. Taurolidine treatment did not cause measurable cell death, as shown by the fact that cells remained trypan blue negative throughout the 4 day culture following treatment. Additionally, these cells did not demonstrate evidence for fragmentation of DNA (TUNEL positivity) when assayed 6 hours after treatment. DNA fragmentation has been used to assay for apoptosis in fibroblast cell lines (Kim, et al., "Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts," *Proc Natl Acad Sci USA* 92:9500-9504 (1995)), including, in particular, the TUNEL assay (Gansauge, et al., "The induction of apoptosis in proliferating human fibroblasts by oxygen radicals is associated with a p53- and p21^{WAF1/CIP1} induction," *FEBS Letters* 404:6-10 (1997)). However, some fibroblast

cell lines have not exhibited DNA degradation, and apoptosis was identified by changes in cell morphology and detachment of cells from the culture vessel (Boyle, et al., "Apoptosis in C3H-10T1/2 cells: roles of intracellular pH, protein kinase C, and the Na⁺/H⁺ antiporter," *J Cell Biochem* 67:231-240 (1997)). Additionally,
5 these studies examined cells for evidence of apoptosis 24-48 hours after treatment with the apoptogenic agent. While evidence for DNA fragmentation of fibroblast or endothelial cells was not found, analysis by flow cytometry did reveal an increase in cell fragmentation.

Taurolidine induces apoptosis in monocytes, granulocytes, and numerous
10 leukemic cell lines. In all cells tested, it was as efficient an apoptogenic agent as the protein synthesis inhibitor anisomycin. Intravenous administration of taurolidine does not cause detectable alterations in hematologic variables, including white cell count (Browne, M.K., "Pharmacological and clinical studies with taurolin." In *Taurolin, Ein Neues Konzept zur Antimikrobiellen*
15 *Chemotherapie Chirurgischer Infektionen*, Brückner, W.L. and Pfirrmann, R.W. (eds), München-Wien-Baltimore, Urban & Schwarzenberg, p. 51-60 (1985); Browne, et al., "A controlled trial of taurolin in established bacterial peritonitis," *Surg Gynecol Obstet* 146:721-724 (1978); and Williats, et al., "Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome," *Crit Care*
20 *Med* 23:1033-1039 (1995)). Taurolidine provides a treatment for a variety of leukemic diseases due to its ability to induce apoptosis in leukemic cells and cells in whole blood, in conjunction with the absence of a generalized toxicity in human subjects.

Induction of apoptosis in monocytic cells by taurolidine appeared to be
25 independent of any effects the drug may have on LPS. In fact, taurolidine induced apoptosis in monocytic cells in the absence of LPS treatment. Thus, in addition to its potential utility as a treatment for sepsis previously reported by others, we have found that taurolidine is a very effective, selective inducer of apoptosis in

monocytic and myeloid cells and has utility in the treatment of certain leukemias, including monocytic and myeloid leukemias.

Example 1: In Vitro Screening Test for Taurolidine Treatment

5 An *in vitro* screening test is performed on a patient's blood to determine if the monocytic, myeloid and/or leukemia cells would respond to taurolidine therapy by exhibiting apoptosis.

 A patient's peripheral blood leukocytes are isolated from heparinized blood by centrifugation using Histopaque, Ficoll-Hypaque, or any other suitable
10 methodology. After separation, the isolated leukocytes are suspended in RPMI +10%BCS. Aliquots of the suspended cells are treated with 10-100 $\mu\text{g/ml}$ taurolidine for 4-6 hours. Cells treated with the vehicle solution alone are used as controls. The presence of apoptosis is measured as the degree of DNA
15 fragmentation using either the agarose gel electrophoresis or the TUNEL assay. A high degree of apoptosis observed *in vitro* with the patient's leukemia cells is indicative of a favorable prognosis upon *in vivo* taurolidine treatment, while a minimal degree of apoptosis suggests alternative treatment might be preferable.

Example 2: In Vivo Taurolidine Treatment

20 To decrease the number of monocytic and/or myeloid leukemia cells, a patient with monocytic and/or myeloid leukemia is treated with about 10 to 500 mg/kg body weight taurolidine administered either intravenously or intraperitoneally. The patient's response to treatment is monitored by a decrease in WBC count and examining the patient's leukocytes for a decrease in leukemia
25 cells. Treatment can be continued as necessary.

Example 3: In vivo Taurolidine Treatment to Reduce Coagulopathies

 To decrease the hypercoagulable state associated with TF expression on circulating leukemia cells, a patient with leukemia and an associated coagulopathy

- is treated with about 10 to 500 mg/kg body weight taurolidine administered either intravenously or intraperitoneally. In addition, treatment can be given prior to, or concurrently with, standard cancer chemotherapy, in order to reduce the incidence or severity of thrombotic complications. The patient's response to treatment is
- 5 monitored by any of a variety of standard hematologic measures of hypercoagulability or DIC. These measures include prolongation of the prothrombin time, elevated levels of fibrin degradation products (FDP), elevated levels of fibrin D-Dimer, and hypofibrinogenemia. A positive response to treatment is indicated by a return of these measures toward normal (control) levels.
- 10 Treatment can be continued as necessary.

I CLAIM:

1. A method of rendering leukemia cells apoptotic comprising contacting said cells with an effective amount of taurolidine.

2. A use of taurolidine to manufacture a pharmaceutical composition for treatment of leukemia.

3. A method of decreasing the hypercoagulable state associated with TF expression on leukemia cells comprising contacting said cells with an effective amount of taurolidine.

4. A use of taurolidine to manufacture a pharmaceutical composition for treatment of hypercoagulability associated with TF expression on leukemia cells.

5. A method of screening leukemia patient's blood to determine effectiveness of taurolidine treatment comprising the step of

- a. isolating peripheral blood leukocytes from blood;
- 5 b. treating a first aliquot of said leukocytes with a taurolidine solution to form a treated cell suspension;
- c. treating a second aliquot of said leukocytes with said taurolidine solution vehicle to form a control cell suspension; and
- f. comparing the degree of apoptosis in said treated cell suspension and
- 10 said control cell suspension.

6. A method for treating a leukemia patient with taurolidine, comprising the steps of administering to said patient an effective amount of taurolidine to render leukemia-causing cells in said patients apoptotic.

7. The method of claim 6, wherein said amount of taurolidine is administered intravenously.

8. The method of claim 6, wherein said amount of taurolidine is administered intraperitoneally.

9. The method of claim 6, wherein said effective amount of taurolidine is from about 10 to about 500 milligrams per kilogram body weight.

11. The method of Claim 6, wherein said effective amount of taurolidine is about 150 milligrams per kilogram body weight.

12. A method for treating a leukemia patient with taurolidine, said patient exhibiting coagulopathy caused by TF expression on leukemia cells, comprising the steps of administering to said patient an effective amount of taurolidine to reduce coagulopathy in said patient.

13. The method of claim 12, wherein said amount of taurolidine is administered intravenously.

14. The method of claim 12, wherein said amount of taurolidine is administered intraperitoneally.

15. The method of claim 12, wherein said effective amount of taurolidine is from about 10 to about 500 milligrams per kilogram body weight.

16. The method of Claim 12, wherein said effective amount of taurolidine is about 150 milligrams per kilogram body weight.

AMENDED CLAIMS

[received by the International Bureau on 20 October 1998 (20.10.98);
original claims 11-16 amended and renumbered 10-15;
remaining claims unchanged (1 page)]

7. The method of claim 6, wherein said amount of taurolidine is administered intravenously.

8. The method of claim 6, wherein said amount of taurolidine is administered intraperitoneally.

9. The method of claim 6, wherein said effective amount of taurolidine is from about 10 to about 500 milligrams per kilogram body weight.

10. The method of Claim 6, wherein said effective amount of taurolidine is about 150 milligrams per kilogram body weight.

11. A method for treating a leukemia patient with taurolidine, said patient exhibiting coagulopathy caused by TF expression on leukemia cells, comprising the steps of administering to said patient an effective amount of taurolidine to reduce coagulopathy in said patient.

12. The method of claim 11, wherein said amount of taurolidine is administered intravenously.

13. The method of claim 11, wherein said amount of taurolidine is administered intraperitoneally.

14. The method of claim 11, wherein said effective amount of taurolidine is from about 10 to about 500 milligrams per kilogram body weight.

15. The method of Claim 11, wherein said effective amount of taurolidine is about 150 milligrams per kilogram body weight.

1/15




Fig. 1

2/15

Fig. 2A







Fig. 2B



3/15

Fig. 3A**Fig. 3B**

4/15

Fig. 4A





Fig. 4B



5/15

Fig. 5A





Fig. 5B



6/15

Fig. 6A





Fig. 6B



7/15

Fig. 7A





Fig. 7B



8/15

Fig. 8A





Fig. 8B



9/15

Fig. 9A





Fig. 9B



10/15

Fig. 10A





Fig. 10B



11/15

Fig. 11A









Fig. 11B



12/15

Fig. 12A**Fig. 12B****Fig. 12C****Fig. 12D**

13/15




Fig. 13

14/15

Fig. 14A





Fig. 14B



15/15

Fig. 15A




Fig. 15B





Fig. 15C



INTERNATIONAL SEARCH REPORT

national Application No
PCT/US 98/10494

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/54

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|
| A | BILLING ET AL.: "the effect of taurolin on endogenous immunity and pathogen elimination in human peritonitis" LANGENBECKS ARCH CHIR, vol. 377, no. 3, - 1992 pages 180-185, XP002076648 see abstract ----- | 1-16 |

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 September 1998

Date of mailing of the international search report

24/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Trifilieff-Riolo, S

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/ 10494

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1, 6-16
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1, 6-16
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.